MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target

SIMPLE SUMMARY: Around 3% of patients with Non-Small-Cell Lung Cancer (NSCLC) harbour a MET exon 14 skipping mutation (METex14). Early mutation identification is important for accurate treatment of these patients because they receive more benefit from chemotherapy than from immune checkpoint inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Spitaleri, Gianluca, Trillo Aliaga, Pamela, Attili, Ilaria, Del Signore, Ester, Corvaja, Carla, Corti, Chiara, Uliano, Jacopo, Passaro, Antonio, de Marinis, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571577/
https://www.ncbi.nlm.nih.gov/pubmed/37835473
http://dx.doi.org/10.3390/cancers15194779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571577/
https://www.ncbi.nlm.nih.gov/pubmed/37835473
http://dx.doi.org/10.3390/cancers15194779

Ejemplares similares